AUM Biosciences and GLG are organising a panel discussion to exchange views about the emerging business models in drug development.

GLG office, Singapore, 14 May 2019 between 6.30 PM and 8.30 PM

Biotech companies commercialize new ideas and innovations through their business models. The same idea or innovation taken to market with different business models will yield different economic outcomes.

To discuss the various emerging business models in drug development, AUM Biosciences and GLG are organising a panel discussion with three industry experts.

The panel will also exchange views about the risks and opportunities involved in the future of drug development.

The speakers on the panel are:

For details about the event, contact: Yi Shun Tey | ytey@glggroup.com | +65 8614 8003

Note: The event is complimentary for all attendees.

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit www.aumbiosciences.com